IPG Photonics (IPGP)
NASDAQInformation TechnologySemiconductorsSnapshot 2026-09-09
$80.29+0.92%
Close 2026-09-09 · 1-day change
NASDAQInformation TechnologySemiconductorsSnapshot 2026-09-09
Broken: Primary pillar broken — EPS around $0.40 next quarter: EPS $0.58 vs $0.40 target.
IPG Photonics grows revenue about 11% yearly, driven by fiber laser demand. Gross margins improve to about 38.5% next quarter. The company is resolving patent issues with Trumpf. Profit per share is expected near $0.40 next quarter.
Earnings guidance was cut recently, signaling risk to growth. Patent litigation and legal costs may pressure profits. The stock trades at a high PE of 69, above peers at 45.
The price is about 11% below our fair value near $110. Analysts expect roughly 11% revenue growth. Our view aligns with this but notes risks from guidance cuts and litigation.
Breaks if: EPS falls below $0.25 next quarter
Breaks if: Gross margin falls below 37% next quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a mix of growth and risk. The company is pursuing strategic initiatives like the Lumibird Medical acquisition, which could expand its market presence, but faces challenges in execution and legal matters.
The current valuation is considered expensive compared to peers, indicating that the market has high expectations for future performance. There is a notable expectations gap, suggesting that investors may be anticipating significant growth.
Recent financial performance has been neutral, with some positive momentum noted, but the company has experienced erratic earnings surprises. The risk of missing future earnings estimates is low, but the trend in earnings surprises is declining.
The thesis hinges on key factors such as the company's ability to execute on growth initiatives, the resolution of patent litigation, and broader market conditions like potential interest rate cuts by the Fed. Additionally, the performance of sector leaders could influence IPGP's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a more favorable outlook. The planned acquisition of Lumibird Medical is expected to expand advanced solutions. There are no new threats identified that could weaken this position.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on enhancing gross profit margins through operational efficiencies.
Breaks if: New patent litigation or unresolved disputes persist beyond 2026
Address ongoing patent infringement litigation with Trumpf SE & Co. KG, including appeals and contingency measures to support affected products.
Stated in 2 quarters including 2026-Q1 and the March 2026 announcement. The litigation affects less than 1% of total sales and IPG is implementing contingency measures and appealing. The priority is recurring with ongoing legal developments, showing persistent focus but limited financial impact disclosed.
“Settlement of litigation matters recorded; ongoing patent litigation with Trumpf continues.”
Breaks if: Revenue falls below $260M next quarter
Over the next 1 to 3 years, IPGP's performance will depend on its execution of strategic priorities and external market conditions. Not investment advice.